Arresting Aneurysm Progression (AAA)

Gertz David, HUJI, School of Medicine - IMRIC, Medical Neurobiology

A Minimally Invasive, Laser-Based Therapeutic Approach


Abdominal Aortic Aneurysm (AAA)

Development Stage

In-vitro studies show that LLLI inhibits processes central to the pathogenesis of aneurysm

Patent Status

Patent Pending

Market Size

The worldwide AAA market is valued at $1-1.2B annually.


  • A Low Level Laser Irradiation (LLLI) addresses the need for improved therapy for AAA, a leading cause of death in the USA, accounting for more than 15,000 deaths every year.
  • The LLLI enhances thickening of the arterial wall, thus reducing the risk of aneurysm rupture.
  • As published in Lasers in Surgery and Medicine (38:779-786, 2006), in-vitro studies by Prof. Gertz’s group showed that LLLI stimulates smooth muscle cell proliferation, stimulates collagen synthesis, modulates the equilibrium between regulatory matrix remodeling enzymes, and inhibits pro-inflammatory IL-1-b gene expression.

Our Innovation

  • A novel, minimally invasive procedure for arresting progression of AAA.
  • The laser irradiation therapy will be applied through a laparoscopic procedure.
  • The LLLI offers a new alternative for high risk patients, avoiding most complications of currently available treatments, and may shorten hospitalization time.

Development Milestones

  • 12-18 months animal study of small (80) and large (20) animals with AAA in-vivo model.
  • Development of the LI-LAP catheter for laparoscopic procedures
  • Clinical studies of the proposed procedure are planned for end of 2008

The Opportunity

  • Every year, 250,000-300,000 patients are diagnosed with AAA in the US alone.
  • 40,000 of these patients are treated with endovascular stenting or open AAA surgery.
  • The proposed procedure will offer a less invasive alternative to all surgical patients suffering from AAA, and will provide the sole alternative to high-risk patients.

Patent Status

Granted US 8,961,502

Contact for more information:

Shoshana Keynan
VP, Head of Business Development, Healthcare
Contact ME: